BMO Capital Maintains Buy Rating on Gilead Sciences with $130 Price Target

Gilead Sciences (GILD) received a Buy rating from BMO Capital, with a price target of $130.00. The company's shares opened at $115.50. The analyst consensus rating is Strong Buy, with an average price target of $125.30, representing an 8.48% upside. Gilead Sciences reported a quarterly revenue of $7.08 billion and a net profit of $1.96 billion for the quarter ending June 30.

Gilead Sciences (GILD) has announced the acquisition of Interius BioTherapeutics for $350 million. This strategic move aims to enhance Gilead's cell-therapy expertise by incorporating Interius's in-vivo platform, which enables the generation of CAR T-cells directly within the patient's body. This approach offers a more durable and long-lasting therapeutic effect by inserting DNA into the patient's genome [1].

Interius BioTherapeutics' technology represents a significant advancement in CAR-T therapy, which is currently limited by complex manufacturing processes and high costs associated with external cell modification. Gilead's acquisition signals its continued investment in innovative approaches to cell therapy as part of its broader oncology strategy [2].

The acquisition is expected to reduce Gilead's adjusted per-share earnings by 23 cents to 25 cents this year. This financial impact underscores the company's commitment to integrating cutting-edge technology into its portfolio while managing potential earnings pressures [1].

In other financial news, Gilead Sciences recently reported improved quarterly revenues and net income, raised its full-year 2025 guidance, declared its third-quarter dividend, and authorized a US$6.0 billion share repurchase program. These moves indicate a strong focus on capital return and management confidence in future performance [3].

Gilead Sciences' shares opened at $115.50 on July 2, 2025, following the acquisition announcement. The company received a Buy rating from BMO Capital with a price target of $130.00. The analyst consensus rating is Strong Buy, with an average price target of $125.30, representing an 8.48% upside [4].

References:
[1] https://www.tradingview.com/news/DJN_DN20250821006434:0-gilead-sciences-to-buy-interius-biotherapeutics-for-350-million/
[2] https://www.geneonline.com/gilead-sciences-acquires-interius-biotherapeutics-for-350-million-to-advance-in-vivo-cell-therapy/
[3] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/how-gileads-us6-billion-buyback-and-upward-guidance-could-sh
[4] https://www.sharewise.com/us/news_articles/Gilead_Sciences_GILD_Tops_Q2_Earnings_and_Revenue_Estimates_Zacks_20250807_2340